-

Kenvue Debuts on Fortune 500 List

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company’s debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation.

“Being named to the Fortune 500 list marks a significant milestone for Kenvue,” said Thibaut Mongon, Chief Executive Officer. “Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact.”

Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future.

Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies.

About Kenvue

Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

Contacts

Investor Relations:
Sofya Tsinis
Kenvue_IR@Kenvue.com

Media Relations:
Melissa Witt
Media@Kenvue.com

Industry:

Kenvue

NYSE:KVUE
Release Versions
English

Contacts

Investor Relations:
Sofya Tsinis
Kenvue_IR@Kenvue.com

Media Relations:
Melissa Witt
Media@Kenvue.com

More News From Kenvue

LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion

SUMMIT, N.J.--(BUSINESS WIRE)--Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health. The multiyear education and advocacy campaign is desig...

Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair

VIENNA--(BUSINESS WIRE)--Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna. Abstracts presented will share new evidence demonstrating how science-backed ingredients including niacinamide, trehalose, colloidal oat and 5% minoxidil can help address some of the most common skin and hair concerns consumers experience, including acne, oily s...

Kenvue Declares Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026. About Kenvue Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson...
Back to Newsroom